Lifestyle and Pharmacological Interventions in Hypertrophic Cardiomyopathy

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

April 1, 2019

Primary Completion Date

February 28, 2022

Study Completion Date

March 31, 2022

Conditions
Hypertrophic Cardiomyopathy
Interventions
DRUG

Sacubitril/Valsartan

Sacubitril / Valsartan as a pharmacological agent shall be studied to verify its effects on cardiac morphology and physiology of hypertrophic cardiomyopathy patients.

BEHAVIORAL

Lifestyle

A 4-month lifestyle intervention will consist of two integrated components i.e. physical activity and dietary supplementation with inorganic nitrate. The physical activity component aims to increase daily physical activity level by at least 2000 steps/day from baseline (e.g. walking for approximately 30 minutes), at least 5-7 days per week. The second component of the lifestyle intervention is a dietary supplementation with inorganic nitrate. A single dose of inorganic nitrate given in the form of concentrated nitrate-rich beetroot juice (NO3-, BEET IT Sport, James White Drinks Ltd., Ipswich, UK) containing 6 mmol of NO3- in 70 ml bottle.

Trial Locations (1)

Unknown

Newcastle NHS, Newcastle

All Listed Sponsors
collaborator

University Hospital Regensburg

OTHER

collaborator

Assistance Publique - Hôpitaux de Paris

OTHER

collaborator

Azienda Ospedaliero-Universitaria Careggi

OTHER

collaborator

Institute of Cardiovascular Diseases, Vojvodina

OTHER

lead

Newcastle-upon-Tyne Hospitals NHS Trust

OTHER

NCT05366101 - Lifestyle and Pharmacological Interventions in Hypertrophic Cardiomyopathy | Biotech Hunter | Biotech Hunter